Eman Abdelsameea

693 total citations
67 papers, 441 citations indexed

About

Eman Abdelsameea is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Eman Abdelsameea has authored 67 papers receiving a total of 441 indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Epidemiology, 47 papers in Hepatology and 9 papers in Surgery. Recurrent topics in Eman Abdelsameea's work include Liver Disease Diagnosis and Treatment (44 papers), Hepatitis C virus research (25 papers) and Liver Disease and Transplantation (21 papers). Eman Abdelsameea is often cited by papers focused on Liver Disease Diagnosis and Treatment (44 papers), Hepatitis C virus research (25 papers) and Liver Disease and Transplantation (21 papers). Eman Abdelsameea collaborates with scholars based in Egypt, India and Libya. Eman Abdelsameea's co-authors include Imam Waked, Asmaa Gomaa, Wael Abdel‐Razek, Mohsen Salama, Ayman Alsebaey, Homie Razavi, Mostafa I. Abuzeid, Chris Estes, Mohamed A. Essa and Maha Elsabaawy and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Eman Abdelsameea

58 papers receiving 435 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eman Abdelsameea Egypt 11 278 273 64 56 37 67 441
Rajani Sharma United States 11 286 1.0× 180 0.7× 82 1.3× 27 0.5× 23 0.6× 27 381
Nehad Hawash Egypt 10 237 0.9× 224 0.8× 59 0.9× 60 1.1× 31 0.8× 27 357
Naoki Kawagishi Japan 12 213 0.8× 248 0.9× 90 1.4× 32 0.6× 45 1.2× 41 434
Isabelle Ollivier‐Hourmand France 9 258 0.9× 312 1.1× 172 2.7× 42 0.8× 44 1.2× 31 431
Jimmy Che‐To Lai Hong Kong 14 465 1.7× 349 1.3× 48 0.8× 38 0.7× 31 0.8× 52 612
Ilaria Serio Italy 9 570 2.1× 366 1.3× 80 1.3× 82 1.5× 34 0.9× 21 750
C.P. Strassburg Germany 11 231 0.8× 288 1.1× 135 2.1× 86 1.5× 56 1.5× 38 571
Naglaa Allam Egypt 10 259 0.9× 272 1.0× 61 1.0× 31 0.6× 18 0.5× 25 364
Jorge Daruich Argentina 12 429 1.5× 479 1.8× 101 1.6× 28 0.5× 31 0.8× 40 641
Jhon Prieto United States 10 159 0.6× 140 0.5× 61 1.0× 62 1.1× 36 1.0× 22 510

Countries citing papers authored by Eman Abdelsameea

Since Specialization
Citations

This map shows the geographic impact of Eman Abdelsameea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eman Abdelsameea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eman Abdelsameea more than expected).

Fields of papers citing papers by Eman Abdelsameea

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eman Abdelsameea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eman Abdelsameea. The network helps show where Eman Abdelsameea may publish in the future.

Co-authorship network of co-authors of Eman Abdelsameea

This figure shows the co-authorship network connecting the top 25 collaborators of Eman Abdelsameea. A scholar is included among the top collaborators of Eman Abdelsameea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eman Abdelsameea. Eman Abdelsameea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Abdelsameea, Eman, et al.. (2025). Unveiling the nexus between direct-acting antivirals in hepatitis C virus elimination and immune response. Clinical and Experimental Medicine. 25(1). 269–269.
2.
Salama, Mohsen, et al.. (2024). Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs). Journal of Hepatocellular Carcinoma. Volume 11. 2115–2132.
3.
Abdelsameea, Eman, et al.. (2024). Exploring the prognostic significance of blood carnitine and acylcarnitines in hepatitis C virus-induced hepatocellular carcinoma. SHILAP Revista de lepidopterología. 14(1). 1 indexed citations
4.
Abdelsameea, Eman, et al.. (2024). Long Noncoding RNA H19 rs3741219 Polymorphism and Risk of Hepatocellular Carcinoma in Egyptian Population. The Egyptian Journal of Hospital Medicine. 94(1). 521–528.
5.
Abdelsameea, Eman, et al.. (2024). Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis. PubMed. 14(4). 95272–95272. 1 indexed citations
6.
Hamdy, Mona, et al.. (2023). Study of transcription factor 7-like 2 (TCF7L2) gene polymorphism in cirrhotic patients with diabetes. SHILAP Revista de lepidopterología. 13(1). 4 indexed citations
7.
Abdelsameea, Eman, et al.. (2023). Epidermal growth factor rs4444903 polymorphismand risk of cholangiocarcinoma. A case control study. Clinical and Experimental Hepatology. 9(2). 138–145.
8.
Abdelsameea, Eman, et al.. (2023). Outcome of direct-acting antiviral treatment in patients with hepatitis C virus/hepatitis B virus coinfection. SHILAP Revista de lepidopterología. 13(1).
9.
Abdel‐Razek, Wael, et al.. (2022). Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C. PLoS ONE. 17(11). e0276592–e0276592. 2 indexed citations
10.
Khalil, Ashraf A., et al.. (2022). Value of Bile Acids in Diagnosing Hepatitis C Virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma. British Journal of Biomedical Science. 79. 10191–10191. 9 indexed citations
11.
Khalil, Ashraf A., et al.. (2021). Role of bile acids in the prediction of hepatocellular carcinoma in HCV-induced liver cirrhosis. SHILAP Revista de lepidopterología. 11(1). 2 indexed citations
12.
Abdelsameea, Eman, et al.. (2021). Lymphoepithelioma-like Hepatocellular Carcinoma: a Case Report and Review of Literature. Journal of Gastrointestinal Cancer. 54(1). 275–281. 6 indexed citations
13.
Abdelsameea, Eman, et al.. (2021). The Putative Role of Natural Killer Cells in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention. 22(8). 2559–2567. 6 indexed citations
14.
Ismail, Faisal, et al.. (2021). Cancer incidence in the Tobruk area, eastern Libya: first results from Tobruk Medical Centre. Epidemiology and Health. 43. e2021050–e2021050. 3 indexed citations
15.
Elsabaawy, Maha, et al.. (2020). FIB-5 versus FIB-4 index for assessment of hepatic fibrosis in chronic hepatitis B affected patients. Clinical and Experimental Hepatology. 6(4). 335–338. 13 indexed citations
16.
Abdelsameea, Eman, et al.. (2020). Direct acting antivirals are associated with more liver stiffness regression than pegylated interferon therapy in chronic hepatitis C patients. Expert Review of Anti-infective Therapy. 19(8). 1053–1059. 6 indexed citations
17.
18.
Youssef, Mohamed, et al.. (2019). <p>On-treatment improvement of an emerging psychosomatic depressive disorder among salmonella carriers: a multicenter experience from Egypt</p>. Infection and Drug Resistance. Volume 12(37). 2573–2582. 2 indexed citations
19.
Alsebaey, Ayman, et al.. (2018). High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. International Journal of Infectious Diseases. 75. 109–114. 37 indexed citations
20.
Estes, Chris, Wael Abdel‐Razek, Eman Abdelsameea, et al.. (2015). Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Alimentary Pharmacology & Therapeutics. 42(6). 696–706. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajani Sharma Breakdown of academic impact, for papers by Nehad Hawash Breakdown of academic impact, for papers by Naoki Kawagishi Breakdown of academic impact, for papers by Isabelle Ollivier‐Hourmand Breakdown of academic impact, for papers by Jimmy Che‐To Lai Breakdown of academic impact, for papers by Ilaria Serio Breakdown of academic impact, for papers by C.P. Strassburg Breakdown of academic impact, for papers by Naglaa Allam Breakdown of academic impact, for papers by Jorge Daruich Breakdown of academic impact, for papers by Jhon Prieto
Rankless by CCL
2026